MARKET

CRMD

CRMD

Cormedix
NASDAQ
2.830
+0.010
+0.35%
After Hours: 2.830 0 0.00% 17:06 09/30 EDT
OPEN
2.810
PREV CLOSE
2.820
HIGH
2.900
LOW
2.770
VOLUME
106.71K
TURNOVER
0
52 WEEK HIGH
8.03
52 WEEK LOW
2.645
MARKET CAP
116.62M
P/E (TTM)
-3.5182
1D
5D
1M
3M
1Y
5Y
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, tod...
GlobeNewswire · 09/07 12:30
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Benzinga · 08/31 18:52
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,100 Today
  Cormedix (NASDAQ:CRMD) has outperformed the market over the past 10 years by 2.86% on an annualized basis producing an average annual return of 14.54%. Currently, Cormedix has a market capitalization of $167.76 million.
Benzinga · 08/16 14:03
--Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
--Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
MT Newswires · 08/12 11:01
BRIEF-Cormedix Inc Posts Q2 Loss Per Share $0.19
BRIEF-Cormedix Inc Posts Q2 Loss Per Share $0.19
Reuters · 08/11 13:50
CorMedix GAAP EPS of -$0.19 beats by $0.02, revenue of $0.02M
CorMedix press release (<span class="ticker-hover-wr...
Seekingalpha · 08/11 12:02
Notable earnings before Thursday's open
Major earnings expected before the bell on Thursday include: Arrival (ARVL) Brookfield Asset Management (<a...
Seekingalpha · 08/10 14:45
Dow Drops Over 100 Points; Verona Pharma Shares Jump
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday.
Benzinga · 08/09 19:11
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is on the development of its lead product candidate, DefenCath, for commercialization in the United States. The DefenCath/Neutrolin is an anti-infective solution, a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis and total parenteral nutrition. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

Webull offers kinds of CorMedix Inc. stock information, including NASDAQ:CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.